Please login to the form below

Not currently logged in
Email:
Password:

Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Abbvie’s Humira (adalimumab) and J&J’s Stelara (ustekinumab) remain the leaders in the market due to the strength of their ability to quickly clear up to 75% of lesions

Latest news

  • Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial

    AbbVie’s Humira (adalimumab) and J&J’s Stelara (ustekinumab) became, and remain, big selling drugs partly on the strength of their ability to quickly clear up to 75% of lesions

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    Of the newer agents, Stelara was the most prescribed, with expenditure at £32m for the period, up 25%. ... This reflects a global picture, with Stelara expected to maintain its lead among the newer agents, Evaluate expecting its sales to global annual

  • Tremfya heads for filing in psoriatic arthritis Tremfya heads for filing in psoriatic arthritis

    Tremfiya (guselkumab) is the follow-up to J&J’s IL-23/IL-12 inhibitor blockbuster Stelara, which is under assault from rival new entrants across immunology indications, most notably Novartis’ ... Cosentyx. While Stelara remains in a solid second

  • Latecomer Lilly preps its IL-23 drug for Crohn’s disease Latecomer Lilly preps its IL-23 drug for Crohn’s disease

    First to market was Johnson &Johnson’s dual IL-12/IL-23 inhibitor Stelara (ustekinumab) for psoriasis, which rapidly achieved blockbuster status with add-on indications in psoriatic arthritis and ... already FDA-approved for psoriasis and require fewer

  • European approval for Skyrizi, hot on the heels of US European approval for Skyrizi, hot on the heels of US

    Two studies compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against its own TNF inhibitor Humira (adalimumab), currently the biggest-selling ... The analysis showed that 56% of patients on risankizumab

More from news
Approximately 14 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for

  • Back to the future Back to the future

    Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics